A conditional maximized sequential probability ratio test for pharmacovigilance

Statistics in Medicine

Volumn 29, Issue 2, 2010, Pages 284-295

  Li, Ngling ^a   Kulldorff, Martin ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adverse events detection; Drug safety surveillance; Pharmacovigilance; Sequential analysis; Sequential probability ratio test (SPRT)

Indexed keywords

VACCINE;

ARTICLE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH SURVEY; HUMAN; NULL HYPOTHESIS; POISSON DISTRIBUTION; POSTMARKETING SURVEILLANCE; SAMPLE SIZE; SEQUENTIAL ANALYSIS; TIME; UNCERTAINTY; VARIANCE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; BIAS (EPIDEMIOLOGY); CHILD; COMPUTER SIMULATION; CONFIDENCE INTERVALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG TOXICITY; EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS; HYPERSENSITIVITY; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; MONTE CARLO METHOD; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHARMACEUTICAL PREPARATIONS; POISSON DISTRIBUTION; PROBABILITY; PRODUCT SURVEILLANCE, POSTMARKETING; RISK; VACCINES; YOUNG ADULT;

EID: 74749106619     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3780     Document Type: Article

References (29)

1. Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, Platt R, Black S, Shinefield H, Chen RT. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology 2005; 16:336-341.
2. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports databases. Drug Safety 2002; 25:381-392.
3. DuMouchel W. Bayesian data mining in large scale frequency tables, with an application to the FDA spontaneous reporting system. American Statistician 1999; 53:177-202.
4. O'Neill RT, Szarfman A. Some US food and drug administration perspectives on data mining for pediatric safety assessment. Current Therapeutic Research 2001; 62:650-663.
5. Lieu AT, Kulldorff M, Davis RL, Lewis EM, Weintraub E, Yih K, Yin R, Brown JS, Platt R. Real-time vaccine safety surveillance for the early detection of adverse events. Medical Care 2007; 45:S89-S95.
6. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM. Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 1997; 99:765-773.
7. DeStefano F. The vaccine safety datalink project. Pharmacoepidemiology and Drug Safety 2001; 10(5):403-406.
8. Wald A. Sequential Analysis. Wiley: New York, 1947.
9. Siegmund DO. Tests and Confidence Intervals. Springer: New York, 1985.
10. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall, CRC: London, Boca Raton, 2000.
11. Fay MP, Huang CY, Twum-Danso NAY. Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls. Clinical Trials 2007; 4:598-610. DOI: 10.1177/1740774507084978.
12. Hocine MN, Musonda P, Andrews NH, Farrington CP. Sequential case series analysis for Pharmacovigilance. Journal of Royal Statistical Society: Series A 2009; 172:213-236.
13. Shewhart WA. Economic Control of Quality of Manufactured Product. American Society for Quality Control, 1931.
14. Wald A. Sequential tests of statistical hypotheses. Annals of Mathematical Statistics 1945; 16:117-186.
15. Abt K. Poisson sequential sampling modified towards maximal safety in adverse event monitoring. Biometrical Journal 1998; 40:21-41.
16. Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Technical Report, 2008. Available from: http://www.populationmedicine. org/content/docs/maxSPRTsubm.pdf.
17. Lorden G. Procedures for reacting to a change in distribution. Annals of Mathematical Statistics 1971; 42:1897-1908.
18. Lai TL. Sequential changepoint detection in quality-control and dynamical-systems. Journal of the Royal Statistical Society Series B 1995; 57:613-658.
19. Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiology and Drug Safety 2008; 16:1275-1284.
20. Dwass M. Modified randomization tests for nonparametric hypotheses. Annals of Mathematical Statistics 1957; 28:181-187.
21. Jennison C, Turnbull BW. Repeated confidence intervals for group sequential clinical trials. Controlled Clinical Trials 1984; 5:33-45.
22. Jennison C, Turnbull BW. Repeated confidence intervals for the median survival time. Biometrika 1985; 72:619-625.
23. Jennison C, Turnbull BW. Interim analyses: the repeated confidence interval approach. Journal of the Royal Statistical Society, Series B (Methodological) 1989; 51:305-361.
24. Lan K, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
25. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Ellis Horwood: Chichester, 1983.
26. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
27. Gee J, Naleway A, Shui I. Vaccine safety datalink project: monitoring the safety of quadrivalent human papillomavirus vaccine (HPV4). Presented at the Advisory Committee on Immunization Practices Meeting, Atlanta, GA, October 2008.
28. Evans S. Statistical methods of signal detection. In Pharmacovigilance, Mann RD, Andrews EB (eds). Wiley: Chichester, U.K., 2002; 273-279.
29. Evans S. Sequential probability ratio tests applied to public health problems. Controlled Clinical Trials 2003; 24:67S.